Autopsy reference for central comparison
FTLD-tau and FTLD-TDP are defined neuropathologically, providing a strong reference standard for the headline disease comparison.
↳ Methods, Penn biomarker cohort participants
Across tauopathies-Alzheimer's disease (AD), frontotemporal lobar degeneration due to tau (FTLD-tau)-we compared cerebrospinal fluid (CSF) biomarkers of phosphorylated-tau (p-tau) p-tau181, p-tau212, tau368, total tau (t-tau), and the tau368/t-tau ratio, and tested differentiation from non-tau (FTLD-TDP, neuronal α-synuclein disease (αSyn), and controls). In AD, CSF p-tau181 and p-tau212 were significantly higher than in all other groups, including FTLD-tau, while tau368/t-tau was significantly lower. With the aim to combine tau phosphorylation biomarkers (p-tau181 and p-tau212) with biomarkers for severity of tau pathology (tau368), we made ratios between these biomarkers and examined their diagnostic accuracy in FTLD after excluding high/intermediate AD neuropathologic change (ADNC). CSF p-tau181 and p-tau212, as well as p-tau181/tau368 and p-tau212/tau368, were higher in FTLD-tau compared with non-tau groups, and the diagnostic accuracy to discriminate FTLD-tau from FTLD-TDP improved. Levels of the ratios were increased in behavioral and primary progressive aphasia variants of tauopathies when compared to FTLD-TDP. Furthermore, the biomarkers showed significant correlation with both FTLD-tau and AD tau burden at autopsy across brain regions. These results suggest unique patterns of increased relative levels of p-tau epitopes in CSF among ADNC and FTLD-tau could improve the diagnosis of tauopathies and inform inclusion criteria in clinical trial design.
CSF p-tau181 and p-tau212, as well as p-tau181/tau368 and p-tau212/tau368, were higher in FTLD-tau compared with non-tau groups, and the diagnostic accuracy to discriminate FTLD-tau from FTLD-TDP improved.
small retrospective subgroups, post hoc PSP exclusion, and inconsistent AUC reporting limit the claimed incremental accuracy
In AD, CSF p-tau181 and p-tau212 were significantly higher than in all other groups, including FTLD-tau, while tau368/t-tau was significantly lower.
autopsy-defined AD comparisons and reported group medians consistently support the stated biomarker pattern
Levels of the ratios were increased in behavioral and primary progressive aphasia variants of tauopathies when compared to FTLD-TDP.
very small bvFTD groups and supplementary PPA analyses limit clinical-subtype inference
the biomarkers showed significant correlation with both FTLD-tau and AD tau burden at autopsy across brain regions.
small exploratory correlations and incomplete within-FTLD significance limit the breadth of the statement
Derived from the full evaluation — not a separate score.
Strengths
FTLD-tau and FTLD-TDP are defined neuropathologically, providing a strong reference standard for the headline disease comparison.
↳ Methods, Penn biomarker cohort participants
The study targets the absence of reliable fluid biomarkers for FTLD-tau and connects the proposed markers to clinical-trial selection and differentiation of overlapping syndromes.
↳ Introduction, paragraph 1; Conclusions
The analysis reports assay precision, FDR correction, bootstrap confidence intervals, and blinded case-level image quantification.
↳ Methods, Biomarker measurements; Microscopy; Statistical analyses
Limitations
The Results and Discussion report materially different AUCs for FTLD-tau versus FTLD-TDP, changing the apparent size of tau368’s incremental benefit.
↳ Results, FTLD ROC analysis; Discussion, FTLD diagnostic-performance paragraph
Four PSP cases were removed from the main ADNC-negative analysis after being identified as tau368-ratio outliers, while analyses retaining them appear only in supplementary material.
↳ Results, “CSF p-tau/tau368 ratios improve the diagnostic accuracy…”, paragraph 1
The Conclusions predict fewer false results and improved diagnosis despite a small, single-biobank proof-of-concept cohort with no external validation.
↳ Discussion, limitations paragraph; Conclusions
The autopsy-defined FTLD comparison and rare paired CSF–pathology material support a meaningful early contribution. Methodological credit is tempered by the post hoc removal of PSP cases based on tau368-ratio behaviour, small FTLD subgroups, and lack of external validation. The principal reporting problem is that the Results and Discussion provide different AUCs for the same central comparisons, while the manuscript also calls a p=0.057 correlation significant and invokes mediation without a mediation analysis. The limitations section appropriately describes the work as initial validation, but the Conclusions make stronger claims about improved diagnosis and reduced false results.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
The study tests p-tau/tau368 ratios against autopsy-defined FTLD pathology in a setting with no established fluid biomarker, providing a genuine but preliminary advance. Incremental value is clearest for p-tau181 and is limited by small subgroups and inconsistent performance reporting.
there are no robust and reliable fluid biomarkers specific to FTLD-tau
Autopsy reference diagnoses, assay precision, bootstrap AUC intervals, multiplicity correction, and blinded image quantification support the design. Methodological Rigour is constrained by the pathology-enriched spectrum, post hoc PSP exclusion, internally selected Youden cutpoints, unreported assay/pathology blinding, and unreconciled central analysis counts.
Analyses revealed that FTLD-tau PSP cases were outliers for tau368 ratio levels
The question-to-analysis sequence is followable, but central AUCs differ between the Results and Discussion and sensitivity improvement is claimed without corresponding sensitivity estimates. The mediation and significant-correlation wording also exceeds the reported analysis.
CSF tau368 was negatively correlated with tau burden, although this did not reach significance
The paper engages prior p-tau, MTBR-tau, PSP, and FTLD biomarker findings and explicitly acknowledges limited generalizability and the need for replication. Positioning remains below the stronger band because the Conclusions make clinical-improvement claims stronger than the proof-of-concept evidence supports.
replication and extension will be required before these assays can be applied for widespread clinical use
Caveats4 of 4 checks
AUC reporting does not consistently label the PSP inclusion basis, logistic-model effects are called hazard rates rather than odds ratios, and the correlation-method descriptions differ between Methods and Figure 4.
Ethics approval: declared
126 references in manuscript 126 of 126 checkable references found in an index
References not verified automatically are resolved manually within 24 hours.
No retraction or expression of concern found in Crossref (includes Retraction Watch).
Sources: Crossref (incl. Retraction Watch) ✓
The authors describe this as a proof-of-concept study in a single rare autopsy cohort with small sample sizes, requiring future replication in larger cohorts before clinical use.
“Accurate diagnosis will support recruitment for clinical trials and will allow patients to receive appropriate therapy.”
The paper names who would act on the findings (clinical trial recruiters and patients receiving therapy) and the purpose (diagnosis and differentiation of FTLD spectrum disorders).
Neurologists and clinical trial teams would use CSF p-tau/tau368 ratio assays to distinguish FTLD-tau from FTLD-TDP, improving diagnosis and trial enrollment.
The findings need replication in larger, more diverse cohorts, including sporadic cases and plasma-based testing, before the assays can be applied for widespread clinical use.
Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3
AI-generated, human-governed. Something look off? Contact us to request a review.
Keep reading
Other papers Nabu has evaluated blind, starting with the same field.
2026 · Neurology and psychiatry
aggregates enriched during the growth phase downregulated homeostatic microglial markers and induced TLR4-mediated microglial activation, cytokine production, and complement activation, leading to synaptic engulfment and severe disruption of neuronal activity
Tentative2026 · Basic medicine
even brief tau oligomer exposure induces lasting bipartite synapse dysfunction and presenting a timeline of progressive pre- and post-synaptic degeneration.
Tentative